Trial · NCT05348148
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | alleviating darkness of shiners | Change from baseline darkness of shiners at 1 week after treatment. | Change from baseline of the darkness of shiners at 1 week after treatment. |
| Primary | alleviating darkness of shiners | Change from baseline darkness of shiners at 2 weeks after treatment. | Change from baseline of the darkness of shiners at 2 week after treatment. |
| Primary | alleviating darkness of shiners | Change from baseline darkness of shiners at 4 weeks after treatment. | Change from baseline of the darkness of shiners at 4 week after treatment. |
| Primary | alleviating area value of shiners | Change from baseline area value of shiners at 1 week after treatment. | Change from baseline of the area value of shiners at 1 week after treatment. |
| Primary | alleviating area value of shiners | Change from baseline area value of shiners at 2 week after treatment. | Change from baseline of the area value of shiners at 2 week after treatment. |
| Primary | alleviating area value of shiners | Change from baseline area value of shiners at 4 week after treatment. | Change from baseline of the area value of shiners at 4 week after treatment. |
| Secondary | alleviating darkness of shiners among groups | Change from baseline darkness of shiners at 1 week after treatment. | Change from baseline of the darkness of shiners at 1 week after treatment among groups (including oral Levocetirizine group, combined Intranasal Mometasone Furoate with oral Levocetirizine group, and combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group). |
| Secondary | alleviating darkness of shiners among groups | Change from baseline darkness of shiners at 2 week after treatment. | Change from baseline of the darkness of shiners at 2 week after treatment among groups (including oral Levocetirizine group, combined Intranasal Mometasone Furoate with oral Levocetirizine group, and combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group). |
| Secondary | alleviating darkness of shiners among groups | Change from baseline darkness of shiners at 4 week after treatment. | Change from baseline of the darkness of shiners at 4 week after treatment among groups (including oral Levocetirizine group, combined Intranasal Mometasone Furoate with oral Levocetirizine group, and combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group). |
| Secondary | alleviating area value of shiners among groups | Change from baseline area value of shiners at 1 week after treatment. | Change from baseline of the area value of shiners at 1 week after treatment among groups (including oral Levocetirizine group, combined Intranasal Mometasone Furoate with oral Levocetirizine group, and combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group). |
| Secondary | alleviating area value of shiners among groups | Change from baseline area value of shiners at 2 week after treatment. | Change from baseline of the area value of shiners at 2 week after treatment among groups (including oral Levocetirizine group, combined Intranasal Mometasone Furoate with oral Levocetirizine group, and combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group). |
| Secondary | alleviating area value of shiners among groups | Change from baseline area value of shiners at 4 week after treatment. | Change from baseline of the area value of shiners at 4 week after treatment among groups (including oral Levocetirizine group, combined Intranasal Mometasone Furoate with oral Levocetirizine group, and combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05348148/registered